Original Article
Safety and efficacy of growth hormone treatment: GeNeSIS study in Spain
Seguridad y efectividad del tratamiento con hormona de crecimiento: estudio GeNeSIS en España
C. Luzuriaga Tomása, M. Oyarzabal Irigoyenb, E. Caveda Cepasc, L.A. Vázquez Salvid, L.E. García-Péreze,
, el grupo de investigadores españoles del estudio GeNeSIS
Corresponding author
a Unidad de Endocrinología Pediátrica, Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
b Unidad de Endocrinología Pediátrica, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
c Global Scientific Communications, Eli Lilly and Company, Alcobendas Madrid, Spain
d Departamento Médico, Eli Lilly and Company, Alcobendas Madrid, Spain
e Global Medical Affairs, Eli Lilly and Company, Indianapolis, USA
Read
14643
Timeswas read the article
8762
Total PDF
5881
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 55 | 28 | 83 |
| 2025 5 | 170 | 39 | 209 |
| 2025 4 | 175 | 26 | 201 |
| 2025 3 | 157 | 40 | 197 |
| 2025 2 | 129 | 36 | 165 |
| 2025 1 | 103 | 41 | 144 |
| 2024 12 | 87 | 37 | 124 |
| 2024 11 | 71 | 6086 | 6157 |
| 2024 10 | 99 | 43 | 142 |
| 2024 9 | 67 | 54 | 121 |
| 2024 8 | 86 | 60 | 146 |
| 2024 7 | 92 | 37 | 129 |
| 2024 6 | 81 | 29 | 110 |
| 2024 5 | 93 | 45 | 138 |
| 2024 4 | 76 | 35 | 111 |
| 2024 3 | 55 | 33 | 88 |
| 2024 2 | 51 | 36 | 87 |
| 2024 1 | 59 | 31 | 90 |
| 2023 12 | 37 | 25 | 62 |
| 2023 11 | 45 | 28 | 73 |
| 2023 10 | 45 | 24 | 69 |
| 2023 9 | 49 | 18 | 67 |
| 2023 8 | 39 | 25 | 64 |
| 2023 7 | 39 | 23 | 62 |
| 2023 6 | 43 | 27 | 70 |
| 2023 5 | 44 | 25 | 69 |
| 2023 4 | 23 | 18 | 41 |
| 2023 3 | 62 | 28 | 90 |
| 2023 2 | 47 | 14 | 61 |
| 2023 1 | 19 | 35 | 54 |
| 2022 12 | 45 | 40 | 85 |
| 2022 11 | 92 | 52 | 144 |
| 2022 10 | 46 | 44 | 90 |
| 2022 9 | 46 | 42 | 88 |
| 2022 8 | 51 | 44 | 95 |
| 2022 7 | 48 | 44 | 92 |
| 2022 6 | 42 | 32 | 74 |
| 2022 5 | 43 | 31 | 74 |
| 2022 4 | 45 | 49 | 94 |
| 2022 3 | 69 | 34 | 103 |
| 2022 2 | 58 | 25 | 83 |
| 2022 1 | 74 | 27 | 101 |
| 2021 12 | 56 | 34 | 90 |
| 2021 11 | 78 | 60 | 138 |
| 2021 10 | 69 | 70 | 139 |
| 2021 9 | 59 | 40 | 99 |
| 2021 8 | 66 | 38 | 104 |
| 2021 7 | 49 | 28 | 77 |
| 2021 6 | 64 | 42 | 106 |
| 2021 5 | 42 | 29 | 71 |
| 2021 4 | 151 | 46 | 197 |
| 2021 3 | 86 | 43 | 129 |
| 2021 2 | 65 | 23 | 88 |
| 2021 1 | 71 | 23 | 94 |
| 2020 12 | 69 | 30 | 99 |
| 2020 11 | 55 | 21 | 76 |
| 2020 10 | 52 | 17 | 69 |
| 2020 9 | 55 | 21 | 76 |
| 2020 8 | 47 | 41 | 88 |
| 2020 7 | 53 | 30 | 83 |
| 2020 6 | 43 | 18 | 61 |
| 2020 5 | 52 | 18 | 70 |
| 2020 4 | 46 | 18 | 64 |
| 2020 3 | 52 | 21 | 73 |
| 2020 2 | 44 | 16 | 60 |
| 2020 1 | 36 | 16 | 52 |
| 2019 12 | 52 | 33 | 85 |
| 2019 11 | 35 | 14 | 49 |
| 2019 10 | 73 | 30 | 103 |
| 2019 9 | 40 | 23 | 63 |
| 2019 8 | 46 | 30 | 76 |
| 2019 7 | 32 | 28 | 60 |
| 2019 6 | 52 | 23 | 75 |
| 2019 5 | 67 | 28 | 95 |
| 2019 4 | 84 | 26 | 110 |
| 2019 3 | 38 | 27 | 65 |
| 2019 2 | 31 | 18 | 49 |
| 2019 1 | 44 | 23 | 67 |
| 2018 12 | 49 | 33 | 82 |
| 2018 11 | 64 | 37 | 101 |
| 2018 10 | 132 | 20 | 152 |
| 2018 9 | 63 | 14 | 77 |
| 2018 7 | 3 | 0 | 3 |
| 2018 6 | 3 | 0 | 3 |
| 2018 5 | 3 | 0 | 3 |
| 2018 4 | 31 | 0 | 31 |
| 2018 3 | 33 | 0 | 33 |
| 2018 2 | 24 | 0 | 24 |
| 2018 1 | 16 | 0 | 16 |
| 2017 12 | 19 | 0 | 19 |
| 2017 11 | 24 | 0 | 24 |
| 2017 10 | 27 | 0 | 27 |
| 2017 9 | 15 | 0 | 15 |
| 2017 8 | 24 | 0 | 24 |
| 2017 7 | 24 | 0 | 24 |
| 2017 6 | 24 | 5 | 29 |
| 2017 5 | 24 | 10 | 34 |
| 2017 4 | 19 | 7 | 26 |
| 2017 3 | 10 | 6 | 16 |
| 2017 2 | 18 | 13 | 31 |
| 2017 1 | 16 | 7 | 23 |
| 2016 12 | 24 | 11 | 35 |
| 2016 11 | 40 | 14 | 54 |
| 2016 10 | 49 | 19 | 68 |
| 2016 9 | 120 | 11 | 131 |
| 2016 8 | 36 | 7 | 43 |
| 2016 7 | 31 | 12 | 43 |
| 2016 5 | 1 | 0 | 1 |
| 2016 3 | 4 | 0 | 4 |
Show all
